370 related articles for article (PubMed ID: 33475057)
21. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.
Bhat MA; Usman I; Dhaneshwar S
Curr Rev Clin Exp Pharmacol; 2024; 19(3):234-249. PubMed ID: 37859409
[TBL] [Abstract][Full Text] [Related]
22. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.
Ślebioda TJ; Kmieć Z
Mediators Inflamm; 2014; 2014():325129. PubMed ID: 25045210
[TBL] [Abstract][Full Text] [Related]
23. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
24. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease.
Kamada N; Hisamatsu T; Honda H; Kobayashi T; Chinen H; Takayama T; Kitazume MT; Okamoto S; Koganei K; Sugita A; Kanai T; Hibi T
Inflamm Bowel Dis; 2010 Apr; 16(4):568-75. PubMed ID: 19834969
[TBL] [Abstract][Full Text] [Related]
25. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.
Takedatsu H; Michelsen KS; Wei B; Landers CJ; Thomas LS; Dhall D; Braun J; Targan SR
Gastroenterology; 2008 Aug; 135(2):552-67. PubMed ID: 18598698
[TBL] [Abstract][Full Text] [Related]
26. High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease.
Song L; Zhou R; Huang S; Zhou F; Xu S; Wang W; Yi F; Wang X; Xia B
Mediators Inflamm; 2013; 2013():425915. PubMed ID: 24382939
[TBL] [Abstract][Full Text] [Related]
27. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
28. The role of TL1A and DR3 in autoimmune and inflammatory diseases.
Aiba Y; Nakamura M
Mediators Inflamm; 2013; 2013():258164. PubMed ID: 24453414
[TBL] [Abstract][Full Text] [Related]
29. Changes of the cytokine profile in inflammatory bowel diseases.
Műzes G; Molnár B; Tulassay Z; Sipos F
World J Gastroenterol; 2012 Nov; 18(41):5848-61. PubMed ID: 23139600
[TBL] [Abstract][Full Text] [Related]
30. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
Na SY; Kim YS
Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
[TBL] [Abstract][Full Text] [Related]
31. Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome.
Jacob N; Jacobs JP; Kumagai K; Ha CWY; Kanazawa Y; Lagishetty V; Altmayer K; Hamill AM; Von Arx A; Sartor RB; Devkota S; Braun J; Michelsen KS; Targan SR; Shih DQ
Mucosal Immunol; 2018 Sep; 11(5):1466-1476. PubMed ID: 29988118
[TBL] [Abstract][Full Text] [Related]
32. Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease.
Gonsky R; Fleshner P; Deem RL; Biener-Ramanujan E; Li D; Potdar AA; Bilsborough J; Yang S; McGovern DPB; Targan SR
Gastroenterology; 2017 Jul; 153(1):219-232. PubMed ID: 28400196
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
de Mattos BR; Garcia MP; Nogueira JB; Paiatto LN; Albuquerque CG; Souza CL; Fernandes LG; Tamashiro WM; Simioni PU
Mediators Inflamm; 2015; 2015():493012. PubMed ID: 26339135
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.
Liu J; Di B; Xu LL
Cytokine Growth Factor Rev; 2023; 71-72():1-12. PubMed ID: 37455149
[TBL] [Abstract][Full Text] [Related]
36. Treatment of inflammatory bowel disease (IBD).
Pithadia AB; Jain S
Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
[TBL] [Abstract][Full Text] [Related]
37. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
38. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
39. Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.
Castellanos JG; Woo V; Viladomiu M; Putzel G; Lima S; Diehl GE; Marderstein AR; Gandara J; Perez AR; Withers DR; Targan SR; Shih DQ; Scherl EJ; Longman RS
Immunity; 2018 Dec; 49(6):1077-1089.e5. PubMed ID: 30552020
[TBL] [Abstract][Full Text] [Related]
40. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
Clarke K; Chintanaboina J
Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
